Bruce Given, COO & Head of R&D, commented on Lilly discontinuing APOC3 siRNA, unsure of the reason. CEO Christopher Anzalone discussed plans to pay down debt through deals like Sarepta and the strategic importance of obesity programs.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing